women, terminally ill, etc.). For example, in a pediatric oncology trial, having a pediatrician and a parent representative can help ensure that unique ethical issues are fully addressed.

2. Clearly Defined SOPs for Review and Decision-Making

Standard Operating Procedures (SOPs) are critical for consistency and accountability in ethical review. SOPs should define:

• How protocols are submitted and reviewed
• Meeting frequency and quorum requirements
• Criteria for approval, conditional approval, or rejection
• Documentation and communication of decisions
• Review of amendments and safety reports

For example, the CDSCO in India mandates that registered ECs maintain SOPs covering member responsibilities, conflict of interest policies, and timelines for decisions. In the EU, under the Clinical Trials Regulation (CTR 536/2014), coordinated ethics reviews require harmonized SOPs across member states.

3. Comprehensive Protocol Review Criteria

Effective ethical review goes beyond ticking regulatory boxes. The committee must conduct a multi-angle assessment that includes:

• Scientific validity: Is the study methodologically sound enough to justify exposing humans to potential risk?
• Risk-benefit analysis: Are the risks minimized and outweighed by potential benefit?
• Informed consent quality: Is the language understandable and honest?
• Privacy and confidentiality: Are data protection measures in place?
• Subject selection: Are inclusion/exclusion criteria just and fair?

For example, in a placebo-controlled trial for a life-saving treatment, the EC must assess whether the placebo use is ethically defensible when an active comparator may be more appropriate.

4. Informed Consent Document Evaluation

Ethics committees are responsible for ensuring the informed consent form (ICF) is clear, comprehensive, and culturally appropriate. Key elements include:

• Plain-language explanation of study purpose, risks, and procedures
• Participant’s right to withdraw anytime
• Confidentiality of data and biological samples
• Compensation in case of trial-related injury

Many regions require ICFs to be translated into local languages. In Japan and the EU, ECs may require back-translations to verify accuracy. For best practices, review sample templates provided by ISRCTN.

5. Review of Protocol Amendments and Re-Consent

Ethical oversight does not end at protocol approval. Any substantial change to the trial must be reviewed again by the EC. This includes:

• Changes in dosage, administration, or study population
• New risk information or updated SAE trends
• Revised ICFs requiring subject re-consent

For instance, during a COVID-19 trial, mid-study findings about cardiac side effects prompted a protocol amendment and re-consent requirement. A responsive EC will convene quickly to evaluate such changes and prevent enrollment delays.

6. Ongoing Safety and Monitoring Review

Effective ECs engage in continuous monitoring. This includes:

• Review of serious adverse events (SAEs) and suspected unexpected serious adverse reactions (SUSARs)
• Periodic safety update reports (PSURs)
• Annual progress reports and DSMB recommendations

In countries like Canada and Australia, ECs can suspend or withdraw approval based on safety findings, ensuring participant protection even after recruitment ends.

7. Documentation and Archiving of Ethics Committee Decisions

Proper documentation enables traceability, transparency, and regulatory inspection readiness. ECs should maintain:

• Minutes of meetings with detailed deliberations
• Attendance records and member votes
• Correspondence with investigators and sponsors
• Version-controlled documents of ICFs, protocols, and amendments

GCP-compliant archiving of EC records for 3–5 years is essential in jurisdictions such as the US (FDA 21 CFR Part 56) and the EU. During EMA audits, EC document completeness is often a key inspection focus.

8. EC Training and Capacity Building

Committee members must be trained in bioethics, GCP guidelines, regional regulations, and trial methodologies. Many regulatory bodies now mandate initial and refresher trainings. Examples include:

• CDSCO, India: Requires annual training logs and SOPs covering capacity development
• NIH-funded US sites: Mandate HSP/GCP certifications for EC members

Capacity building helps avoid superficial reviews and ensures that members can critically engage with complex trial designs, emerging technologies (e.g., gene therapy), and adaptive protocols.

Conclusion: Strengthening Ethics Review for Responsible Research

A truly effective ethical review process is more than compliance—it is a moral imperative. By focusing on structured procedures, member training, clear communication, and post-approval monitoring, ethics committees can ensure trials are not only scientifically sound but also ethically robust.

With increasing globalization of trials, ECs must stay agile, tech-enabled, and globally harmonized—ensuring that the protection of trial participants remains at the heart of clinical research conduct.